AbbVie files for EMA approval of Skyrizi for Crohn’s disease treatment (ABBV:NYSE)
4 Articles
4 Articles
Rome, 27 Aug. (Adnkronos Salute) - The Italian Drug Agency (Aifa) has approved the refundability in Italy of risankizumab (Skyrizi*), for the treatment of adult patients with moderate to severe active ulcerative colitis, who have experienced an inadequate response, loss of response or intolerance to conventional therapy or biological therapy. It announces, in a known AbbVie.
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease - PressReach
Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn’s disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV) induction NORTH CHICAGO, Ill., Aug. 27, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for SKYRIZI® (risankizumab) for subcutaneous …
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
